Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

MYSTERIOUS: Ocular therapeutix s return on capital employed overview - You Need To See This

Benzinga Pro data, Ocular Therapeutix (NASDAQ:OCUL) reported Q4 sales of $12.31 million. Earnings fell to a loss of $3.85 million, resulting in a 244.9% decrease from last quarter. Ocular Therapeutix reached earnings of $2.66 million and sales of $12.15 million in Q3.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.